In addition, low ENPP1 expression in pre-treatment biopsy samples obtained from breast cancer patients predicted their response to pembrolizumab (anti-PD-1) as a neoadjuvant therapy and distant-metastasis free survival (DMFS) up to 7 y. Here, ENPP1 is linked to breast cancer.